Authors: Topol, EJ Califf, RM Van de Werf, F Willerson, JT Booth, J White, H Clayman, M Deckelbaum, L Lincoff, AM Ohman, EM Bates, E Gibler, WB Hochman, J Kleiman, N Grinfeld, L Aylward, P Armstrong, PW Heikkila, J Vahanian, A Steg, G Bode, C Adgy, AAJ Guetta, V Ardissino, D Savonitto, S Bar, F Simoons, M Kontny, F White, H Sadowski, Z Seabra-Gomes, R Dalby, A Betriu, A Swahn, E Wilcox, R Frye, RL Bertrand, ME DeMets, D Fox, KKA Fuster, V Lee, KL McCarthy, C Waller, M Scherer, J van de Kerkhove, A Kukulewicz, L Booth, JE Del Valle, M Hibert, D Brannon, D

Citation: Ej. Topol et al., Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO randomised trial, LANCET, 357(9272), 2001, pp. 1905-1914

Authors: Topol, EJ Mark, DB Lincoff, AM Cohen, E Burton, J Kleiman, N Talley, D Sapp, S Booth, J Cabot, CF Anderson, KM Califf, RM

Citation: Ej. Topol et al., Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial, LANCET, 354(9195), 1999, pp. 2019-2024